Skip to main content
Top
Published in: Journal of Endocrinological Investigation 8/2021

Open Access 01-08-2021 | Dopamine Agonist | Original Article

Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study

Authors: G. Beccuti, F. Guaraldi, G. Natta, V. Cambria, N. Prencipe, A. Cicolin, E. Montanaro, L. Lopiano, E. Ghigo, M. Zibetti, S. Grottoli

Published in: Journal of Endocrinological Investigation | Issue 8/2021

Login to get access

Abstract

Introduction

Impulse control disorders (ICDs) have been described as a side effect of dopamine agonists (DAs) in neurological as well as endocrine conditions. Few studies have evaluated the neuropsychological effect of DAs in hyperprolactinemic patients, and these have reported a relationship between DAs and ICDs. Our objective was to screen for ICD symptoms in individuals with DA-treated endocrine conditions.

Materials and methods

A cross-sectional analysis was conducted on 132 patients with pituitary disorders treated with DAs (DA exposed), as well as 58 patients with pituitary disorders and no history of DA exposure (non-DA exposed). Participants responded to the full version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease (QUIP).

Results

Compared with the non-DA-exposed group, a higher prevalence of DA-exposed patients tested positive for symptoms of any ICD or related behavior (52% vs. 31%, p < 0.01), any ICD (46% vs. 24%, p < 0.01), any related behavior (31% vs. 17%, p < 0.05), compulsive sexual behavior (27% vs. 14%, p < 0.04), and punding (20% vs. 7%, p < 0.02) by QUIP. On univariate analysis, DA treatment was associated with a two- to threefold increased risk of any ICD or related behavior [odds ratio (OR) 2.43] and any ICD (OR 2.70). In a multivariate analysis, independent risk factors for any ICD or related behavior were DA use (adjusted OR 2.22) and age (adjusted OR 6.76). Male gender was predictive of the risk of hypersexuality (adjusted OR 3.82).

Discussion

Despite the QUIP limitations, a clear sign of increased risk of ICDs emerges in individuals with DA-treated pituitary disorders. Our data contribute to the growing evidence of DA-induced ICDs in endocrine conditions.
Literature
5.
go back to reference Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH (2010) Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 33(1):81–87PubMedPubMedCentral Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH (2010) Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 33(1):81–87PubMedPubMedCentral
9.
go back to reference Falhammar H, Yarker JY (2009) Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust 190(2):97CrossRef Falhammar H, Yarker JY (2009) Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust 190(2):97CrossRef
15.
go back to reference Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB (2014) Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case–control study. Clin Endocrinol (Oxf) 80(6):863–868. https://doi.org/10.1111/cen.12375CrossRef Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB (2014) Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case–control study. Clin Endocrinol (Oxf) 80(6):863–868. https://​doi.​org/​10.​1111/​cen.​12375CrossRef
23.
go back to reference Athanasoulia AP, Ising M, Pfister H, Mantzoros CS, Stalla GK, Sievers C (2012) Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls. Neuroendocrinology 96(3):204–211. https://doi.org/10.1159/000335996CrossRefPubMed Athanasoulia AP, Ising M, Pfister H, Mantzoros CS, Stalla GK, Sievers C (2012) Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls. Neuroendocrinology 96(3):204–211. https://​doi.​org/​10.​1159/​000335996CrossRefPubMed
Metadata
Title
Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study
Authors
G. Beccuti
F. Guaraldi
G. Natta
V. Cambria
N. Prencipe
A. Cicolin
E. Montanaro
L. Lopiano
E. Ghigo
M. Zibetti
S. Grottoli
Publication date
01-08-2021
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 8/2021
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-020-01478-0

Other articles of this Issue 8/2021

Journal of Endocrinological Investigation 8/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.